Related Experiment Video
Updated: Aug 8, 2026
A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model
Published on: October 14, 2016
Establishment and characterization of a new mantle cell lymphoma cell line M-1
Andre Goy1, Yvonne K Remache, Jun Gu
1Department of Lymphoma and Myeloma, The University of Texas-MD Anderson Cancer Center, Houston, Texas 77030, USA. ahgoy@mail.mdanderson.org
Insights
A new M-1 mantle cell lymphoma cell line was established, showing characteristics of the blastoid variant. This cell line demonstrated higher sensitivity to vincristine compared to doxorubicin and cyclophosphamide in preliminary drug testing.
Area of Science:
- Hematology
- Oncology
- Cell Biology
Background:
- Mantle cell lymphoma (MCL) is an aggressive non-Hodgkin lymphoma.
- Limited availability of cell lines hinders MCL research.
- The blastoid variant of MCL presents unique biological and clinical challenges.
Purpose of the Study:
- To establish and characterize a new cell line from a blastoid variant MCL patient.
- To utilize the new cell line as a model for evaluating chemotherapy drug efficacy.
- To contribute a valuable tool for understanding MCL biology.
Main Methods:
- Establishment of the M-1 cell line from peripheral blood mononuclear cells.
- Immunophenotypic analysis (CD markers, sIgM, FMC7) and cytogenetic analysis (t(11;14), cyclin D1 overexpression).
- Cytotoxicity and anti-proliferation assays (MTT) to assess drug sensitivity (doxorubicin, cyclophosphamide, vincristine).
Main Results:
- The M-1 cell line exhibited a mature B-cell phenotype (CD5+, CD19+, CD20+, sIgM+, FMC7+) consistent with MCL.
- Cytogenetic analysis revealed t(11;14) and cyclin D1 overexpression, characteristic of MCL.
- The M-1 cell line showed greater sensitivity to vincristine than to doxorubicin or cyclophosphamide.
Conclusions:
- The M-1 cell line represents a novel and valuable model for studying blastoid variant mantle cell lymphoma.
- This cell line provides a platform for investigating MCL pathogenesis and drug resistance mechanisms.
- The findings highlight the potential of vincristine in MCL treatment, warranting further investigation.
Abstract:
A new mantle cell lymphoma cell line, M-1, was established from peripheral blood mononuclear cells of a patient with a diagnosis of blastoid variant of mantle cell lymphoma in leukemic phase. This cell line showed cell surface antigens identical to the original tumor and demonstrated the profile of a mature B-cell phenotype typical of mantle cell lymphoma: positive for CD5, CD19, CD20, sIgM and FMC7, and negative for CD3, CD10 and CD23. Cytogenetically, the M-1 cell line showed chromosomal alterations similar to the initial clinical specimen, among which a translocation t(11;14) (q13;q32) resulting in the overexpression of cyclin D1 as well as additional abnormalities involving chromosomes 3, 9 and 10. This cell line was used as a model to investigate the activity of the three drugs doxorubicin, cyclophosphamide and vincristine, commonly used in the treatment of mantle cell lymphoma patients. The effect of the drugs was evaluated by a 24 h cytotoxicity test and a 7-days anti-proliferation test using a microculture tetrazolium-based assay (MTT). Both assays indicated a higher sensitivity of the cell line to vincristine when compared to doxorubicin and cyclophosphamide. The characterization of a new mantle cell lymphoma cell line is a unique tool for studying the biology of this subtype of lymphoma for which only a few cell lines have been established.
